title: [Hepatitis C viruses antibodies. Prevalence and their influence on morbidity-mortality in renal transplant recipients, in the last two years of the kidney transplantation program in La Plata city].
abstract: A small series of 34 renal transplanted patients (RTx) were studied, 18 males and 16 females in order to know the prevalence of Anti HCV in this type of patients and their influence on early morbi-mortality. The follow-up mean was 8.44 months SD 6.7, and Age 38.32 SD 13.97. All patients were under the same immunosuppressive scheme, and rejection episodes were treated with methilprednisolone pulses. The results were: 7 (20.6%) Anti HCV seroreactives (R) (EIA II Abbott and Immunoblotting of synthetic Peptides LIA TEK Organon Teknika); and 27 (79.4%) non-serorectives (NR), 14 patients received grafts from cadaveric donor; 4 (57.1%) Anti HCV (R), and 10 (37.0%) Anti HCV (NR). 20 patients have received grafts from lived-related donors: 3 (42.9%) Anti HCV (R), and 17 (63.0%) Anti HCV (NR). 6 (85.7%) of the 7 patients Anti HCV (R) had hepatitis history: 2 chronic hepatitis, 4 acute hepatitis (2HBV) and 2 no A no B (NANBV) and 6 (22.2%) of the 27 Anti HCV (NR). The mean time of hemodialysis treatment before transplantation in the Anti HCV (R) group was of 63.0 months SD27.0, and it was significantly superior (P < 0.05) to the Anti HCV (NR) group with 27.3 months SD 20.7. There were no significant differences between the Anti HCV (R) and (NR) patients with regard to rejection episodes, post-transplant hepatopathies, and survival of graft and patient.
  
  
  CONCLUSIONS
  1) Anti HCV prevalence is of 20.6%. 2) Time of hemodialysis prior to transplantation and an hepatitis history during hemodialysis came out to be significantly higher in Anti HCV (R) RTx. 3) Morbi-mortality is no modified by the presence of Anti HCV during a mean follow-up period of 8.44 months.
authors.affiliation: Instituto de Trasplante de Organos Sólidos, Universidad Nacional de La Plata, Argentina.
authors.forename: J O
authors.initials: JO
authors.lastname: Curciarello
authors.forename: R E
authors.initials: RE
authors.lastname: Adrover
authors.forename: A O
authors.initials: AO
authors.lastname: Chiera
authors.forename: L A
authors.initials: LA
authors.lastname: Touceda
authors.forename: A M
authors.initials: AM
authors.lastname: Giammona
authors.forename: J C
authors.initials: JC
authors.lastname: Raimondi
authors.forename: J C
authors.initials: JC
authors.lastname: Fassi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001118:Argentina; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006526:Hepatitis C / Q000097:blood / Q000401:mortality* / Q000635:transmission; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000097:blood / Q000401:mortality*; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D018937:Hepatitis C Antibodies